5 to 11 years (2 doses of 10 micrograms, 21 days apart).12 years and older (2 doses of 30 micrograms, 21 days apart).The safety and effectiveness of the Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine is based on studies of Comirnaty ® (Original, Original/Omicron BA.4/BA.5). The Pfizer-BioNTech Comirnaty ® Original and Omicron BA.1, bivalent COVID-19 vaccine was shown to increase the immune response against the Omicron BA.1 variant. The Pfizer-BioNTech Comirnaty ® Original and Omicron BA.4/BA.5, bivalent COVID-19 vaccine was shown to increase the immune response against the Omicron BA.4/BA.5 variants. The data determined that the immune response to the vaccine for both age groups was comparable to the immune response of the older participants. 90.7% effective for those 5 to 11 years oldĮffectiveness data supporting the authorization in children ages 6 months to under 5 years are based on a comparison of immune responses in this age group to individuals ages 16 to 25 years.100% effective for those 12 to 15 years old.95% effective in protecting trial participants from COVID-19 for those 16 years and older.EffectivenessĬlinical trials showed that beginning 1 week after the second dose, the Pfizer-BioNTech Comirnaty ® COVID vaccine was about: Its safety and effectiveness in people younger than 6 months has not yet been established. The Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine is approved for people who are 6 months of age and older. Pfizer-BioNTech Comirnaty ® Omicron XBB.1.5 subvariant, monovalent COVID-19 vaccine Its safety and effectiveness in younger people has not yet been established. The Pfizer-BioNTech Comirnaty ® Original and Omicron BA.1, bivalent COVID-19 vaccine is approved as a booster for people who are 12 years of age and older. Pfizer-BioNTech Comirnaty ® Original and Omicron BA.1, bivalent COVID-19 vaccine The Pfizer-BioNTech Comirnaty ® Original and Omicron BA.4/BA.5, bivalent COVID-19 vaccine is approved as a primary series for people who are 6 months of age and older and as a booster for people who are 5 years of age and older. Pfizer-BioNTech Comirnaty ® Original and Omicron BA.4/BA.5, bivalent COVID-19 vaccine This vaccine is also approved as a booster for people age 5 to 11 years as well as 16 years and older. Its safety and effectiveness in people younger than 6 months of age have not yet been established. The vaccine is approved for people who are 6 months of age and older. Pfizer-BioNTech Comirnaty ® COVID-19 vaccine Vaccine review, approval and monitoring.Original and Omicron BA.1 (12 years and older).Original and Omicron BA.4/BA.5 (5 years and older).Original (5 to 11 years as well as 16 years and older).

Primary series in individuals age 6 months and older:

Pfizer bivalent side effects